How to Run Sermorelin Cycle — Safe Protocol & Results

Research published in the Journal of Clinical Endocrinology & Metabolism found that sermorelin acetate administered at 100–200mcg subcutaneously produces measurable growth hormone pulse amplification within the first week—but only when the peptide structure remains intact through storage and reconstitution. Most protocol failures don't stem from incorrect dosing or poor injection technique. They happen because the lyophilised peptide was exposed to temperatures above 8°C during shipping, stored improperly before mixing, or reconstituted with the wrong solution at the wrong pH. A denatured peptide looks identical to an active one under normal observation—you won't know it's inert until you've completed weeks of injections with zero results.

Our team has worked with researchers who've run controlled sermorelin protocols across hundreds of subjects. The gap between a protocol that delivers results and one that wastes time and resources comes down to three execution factors that most peptide suppliers never address: cold chain integrity from synthesis to injection, bacteriostatic water reconstitution at the correct ratio, and timing injections to align with endogenous growth hormone pulsatility.

How do you properly run a sermorelin cycle for measurable growth hormone elevation?

Run sermorelin cycle by reconstituting lyophilised peptide with bacteriostatic water at a 1:1 or 2:1 ratio, injecting 200–300mcg subcutaneously before bed or post-workout for 12–16 weeks, and storing reconstituted solution at 2–8°C for no more than 28 days. Clinical protocols show measurable IGF-1 increases within 4–8 weeks when peptide integrity is maintained throughout the cycle and injection timing aligns with natural GH pulse windows.

Here's what that basic definition misses: sermorelin isn't exogenous growth hormone—it's a growth hormone releasing hormone (GHRH) analogue consisting of the first 29 amino acids of native GHRH-44. It stimulates the anterior pituitary to release endogenous GH in pulses rather than providing a steady-state hormone level. That distinction changes everything about how you time doses, interpret results, and structure washout periods. This article covers the reconstitution process that preserves peptide bioactivity, the injection timing that maximizes pituitary response, the dosing protocols validated in published trials, and the storage mistakes that silently destroy peptide potency weeks before you inject.

Step 1: Source and Verify Lyophilised Sermorelin With Cold Chain Documentation

Peptide quality begins at synthesis—not at your doorstep. Sermorelin acetate must be synthesised through solid-phase peptide synthesis (SPPS) with exact amino acid sequencing verified through HPLC (high-performance liquid chromatography) and mass spectrometry. When you run sermorelin cycle, the peptide you receive should include a certificate of analysis (COA) showing purity ≥98%, endotoxin levels <10 EU/mg, and exact molecular weight confirmation at 3357.9 Da for the acetate salt form.

Cold chain integrity matters more than most researchers realize. Lyophilised sermorelin stored at −20°C remains stable for 24–36 months, but a single temperature excursion above 25°C for more than 48 hours during shipping causes measurable degradation of the peptide backbone—particularly at methionine and tryptophan residues. Real Peptides ships all lyophilised compounds in insulated containers with temperature loggers that document cold chain compliance from facility to delivery. If your peptide arrives without temperature documentation or the packaging feels warm to the touch, request a replacement—there's no way to verify structural integrity after a thermal event.

Verification checklist before reconstitution: COA with HPLC trace showing single dominant peak at correct retention time; vial labeling includes lot number, synthesis date, and storage temperature; lyophilised powder appears as a white to off-white cake without discoloration; peptide was stored continuously at −20°C from synthesis to delivery. Peptides stored at room temperature for more than 72 hours before use show 15–30% potency loss in stability studies—even if the powder looks unchanged.

Step 2: Reconstitute With Bacteriostatic Water at the Correct Concentration

Reconstitution is where most execution errors occur. Sermorelin acetate must be reconstituted with bacteriostatic water (0.9% benzyl alcohol in sterile water for injection)—not sterile water alone, not saline. Bacteriostatic water prevents microbial growth in the reconstituted solution and maintains pH at 5.0–7.0, which is critical for peptide stability. Sterile water without preservative allows bacterial proliferation within 48 hours at refrigeration temperature, and normal saline shifts pH outside the stability range for sermorelin's tertiary structure.

The standard reconstitution ratio for a 5mg vial is 2mL bacteriostatic water, yielding a final concentration of 2.5mg/mL (2500mcg/mL). This concentration allows precise dosing with standard insulin syringes: 0.1mL (10 units on a U-100 syringe) delivers 250mcg. For researchers preferring lower concentration for easier measurement, 2.5mL bacteriostatic water yields 2mg/mL (200mcg per 0.1mL).

Reconstitution technique: Remove both the peptide vial and bacteriostatic water from refrigeration 10 minutes before mixing to reach room temperature—this prevents thermal shock. Swab the rubber stopper with 70% isopropyl alcohol and allow it to air dry completely. Draw the required volume of bacteriostatic water into a sterile syringe. Inject the water slowly down the inside wall of the vial—never directly onto the lyophilised cake. Gently swirl (do not shake) the vial until the powder dissolves completely, typically 30–60 seconds. Shaking introduces air bubbles that denature peptide structure at the air-liquid interface.

Once reconstituted, sermorelin must be stored at 2–8°C (standard refrigerator temperature) and used within 28 days. Stability studies show that reconstituted sermorelin loses approximately 10% potency per week at room temperature but maintains >95% potency for 28 days under continuous refrigeration. After 28 days, even refrigerated peptide shows measurable degradation—discard any remaining solution regardless of appearance.

Step 3: Execute Subcutaneous Injections at Optimal Timing Windows

Sermorelin's mechanism as a GHRH analogue means injection timing relative to endogenous growth hormone pulsatility significantly impacts response magnitude. Growth hormone is released in pulses throughout the 24-hour cycle, with the largest pulse occurring 60–90 minutes after sleep onset and secondary pulses following resistance exercise. When you run sermorelin cycle, timing injections to coincide with these natural pulse windows amplifies pituitary response.

The two validated injection windows: (1) 30 minutes before bedtime, which primes the pituitary immediately before the largest endogenous pulse, or (2) immediately post-resistance training, which capitalizes on exercise-induced GH elevation. Clinical trials published in Metabolism: Clinical and Experimental used bedtime dosing at 200mcg and demonstrated mean IGF-1 increases of 35–50% above baseline after 12 weeks. Post-workout dosing shows similar magnitude but more variable response depending on training intensity.

Subcutaneous injection technique: Sermorelin is administered subcutaneously—not intramuscularly. Preferred injection sites are the lower abdomen (2 inches lateral to the navel) or the lateral thigh. Clean the injection site with alcohol swab and allow to dry. Pinch a fold of skin and insert the needle at a 45-degree angle to a depth of 4–6mm. Inject slowly over 5–10 seconds, withdraw the needle, and apply gentle pressure with a sterile gauze pad. Rotate injection sites with each dose to prevent lipohypertrophy.

Dosing protocols validated in published research: beginners start at 200mcg per injection for the first two weeks to assess tolerance, then increase to 250–300mcg for the maintenance phase. Advanced protocols used in clinical trials go as high as 500mcg, but response plateaus above 300mcg for most subjects—higher doses don't produce proportionally greater GH elevation. Injection frequency is daily for the duration of the cycle. Sermorelin has a half-life of approximately 8–12 minutes in circulation, but its effect on pituitary GH release persists for 3–4 hours post-injection.

Sermorelin Cycle: Protocol Comparison

Key Takeaways

• Sermorelin acetate is a 29-amino-acid GHRH analogue that stimulates endogenous growth hormone release from the anterior pituitary rather than providing exogenous GH directly.
• Reconstitute lyophilised sermorelin with bacteriostatic water at 2–2.5mL per 5mg vial, store at 2–8°C, and discard after 28 days regardless of appearance.
• Run sermorelin cycle at 200–300mcg subcutaneously once daily, injected 30 minutes before bedtime to align with the largest endogenous GH pulse.
• Clinical protocols demonstrate measurable IGF-1 increases of 30–50% above baseline after 12–16 weeks when peptide integrity is maintained throughout storage and reconstitution.
• Temperature excursions above 8°C during shipping or storage cause irreversible peptide denaturation that cannot be detected visually—verify cold chain documentation before use.
• Sermorelin's plasma half-life is 8–12 minutes, but its stimulatory effect on pituitary GH secretion persists for 3–4 hours post-injection.

What If: Sermorelin Cycle Scenarios

What If the Reconstituted Sermorelin Looks Cloudy or Contains Particles?

Discard it immediately—don't inject. Cloudiness or visible particles indicate either microbial contamination (if bacteriostatic water wasn't used), peptide aggregation from improper reconstitution technique (shaking instead of swirling), or degradation from temperature excursion. Properly reconstituted sermorelin should be crystal clear with no visible sediment. If cloudiness appears within the first 24 hours, the peptide was likely compromised before reconstitution. If it develops after several days of refrigerated storage, microbial growth is the probable cause—which means the vial was contaminated during reconstitution or the bacteriostatic water was expired.

What If You Miss a Dose During the Cycle?

Administer the missed dose as soon as you remember if it's within 12 hours of your scheduled time, then resume your normal schedule the next day. If more than 12 hours have passed, skip the missed dose entirely—do not double-dose to compensate. Sermorelin works by amplifying endogenous GH pulses, and doubling the dose doesn't produce a proportional increase in GH secretion due to pituitary receptor saturation. Missing 2–3 doses over a 12-week cycle has negligible impact on overall IGF-1 elevation, but missing doses consistently (more than once per week) reduces cumulative GH exposure and blunts expected outcomes.

What If You Experience Flushing or Headache After Injection?

These are the most common transient side effects and occur in approximately 15–25% of users during the first 2–4 weeks of the cycle. Flushing results from sermorelin-induced vasodilation and typically resolves within 20–30 minutes post-injection. Headaches are believed to stem from acute GH surge effects on cerebral blood flow. Both side effects usually diminish with continued use as the body adapts to the peptide. If symptoms persist beyond four weeks or worsen in intensity, reduce the dose by 25–50mcg for one week, then gradually titrate back up. Persistent severe headaches warrant discontinuation and consultation with a supervising physician to rule out contraindications.

The Unvarnished Truth About Sermorelin Cycle Effectiveness

Here's the honest answer: sermorelin doesn't work like exogenous growth hormone. Not even close. When you inject recombinant human growth hormone (rhGH), you're adding hormone directly into circulation—serum GH levels spike immediately and remain elevated for hours. Sermorelin stimulates your pituitary to release GH it's already producing—which means if your pituitary is significantly impaired or you're past peak GH production years (typically after age 50), the response magnitude is inherently limited. Clinical data shows that sermorelin produces 30–50% increases in IGF-1 levels, while rhGH can elevate IGF-1 by 200–300% or more depending on dose.

The real value of sermorelin isn't raw GH elevation—it's restoration of pulsatile GH secretion patterns that decline with age and metabolic dysfunction. Pulsatile GH release is physiologically different from steady-state elevation: it preferentially stimulates lipolysis and protein synthesis without the same degree of insulin resistance and fluid retention seen with rhGH. Research conducted at the University of Washington School of Medicine found that sermorelin improved body composition (reduced visceral fat, increased lean mass) comparably to low-dose rhGH but with significantly fewer side effects and no suppression of endogenous GH production after discontinuation.

If you're expecting dramatic body recomposition in 8 weeks, you'll be disappointed. If you're looking for a sustainable approach to restore youthful GH pulsatility without shutting down your own production, sermorelin is the more rational choice. The mistake most researchers make is expecting exogenous-GH-level results from a secretagogue—that's not the mechanism, and it's not what the clinical data supports.

When considering how to run sermorelin cycle within your research framework, the focus should be on preserving peptide integrity through proper storage, executing reconstitution without contamination or degradation, and timing injections to physiological GH pulse windows. The protocols described here are drawn from peer-reviewed clinical trials—not anecdotal forums or unverified optimization claims. Small-batch synthesis with verified amino acid sequencing, like what's available through Real Peptides, ensures the compound you're working with matches published research-grade specifications. If the peptide structure isn't intact from synthesis through injection, no dosing protocol will compensate for that foundational failure.

The difference between a sermorelin cycle that produces measurable IGF-1 elevation and one that wastes 12 weeks comes down to execution discipline at every step—from verifying cold chain documentation on delivery, to reconstituting with the correct solution at the correct ratio, to storing reconstituted peptide under continuous refrigeration below 8°C. The peptide doesn't care about your intentions or your protocol design. It only responds to precise handling that preserves its tertiary structure from lyophilisation through subcutaneous administration. Get that foundation right, and the clinical outcomes documented in the literature become reproducible. Get it wrong at any point in the chain, and you're injecting an expensive saline solution that looks identical to active peptide but delivers zero biological effect.